Table 1. Baseline characteristics of patients included in the study. Continuous data are expressed as mean value ± SD and categorical data are expressed as % (number n).
Note: *: p<0.05 marks significant differences. BMI: body mass index, BSA: body surface area, BW: body weight, HF: heart failure, TSH: thyroid stimulating hormone, COPD: Chronic obstructive pulmonary disease, GFR: glomerular filtration rate, TEE: transesophageal echocardiogram, LA: left atrium, LV: left ventricle, TSD: telesystolic diameter,TDD: telediastolic diameter,TSV: telesystolic volume,TDD: telediastolic volume, EF: ejection fraction, ASA: the American Society of Anesthesiologists physical status classification system, AH: arterial hypertension, CAD: coronary artery disease, CMP: cardiomyopathy, Valve: valvular heart disease, CCB: calcium channel blocker, HR: heart rate, BP: blood pressure.
| BASELINE CHARACTERISTICS | PE N = 153 | LE N = 40 | p-value |
|---|---|---|---|
| AGE (years) | 59.7 ± 11.0 | 59.4 ± 11.8 | 0.93 |
| MEN (%) | 70.6 (108) | 62.5 (25) | 0.43 |
| WEIGHT (kg) | 89.3 ± 15.9 | 85.5 ± 16.3 | 0.12 |
| HEIGHT (cm) | 174.3 ± 9.05 | 172.9 ± 8.61 | 0.49 |
| BMI (kg/m2) | 29.3 ± 4.40 | 28.5 ± 4.68 | 0.20 |
| BMI > 25 (%) | 83.7 (128) | 72.5 (29) | 0.07 |
| BSA (m²) | 2.05 ± 0.22 | 1.98 ± 0.20 | 0.06 |
| LEAN BW (kg) | 62.2 ± 11.0 | 59.4 ± 9.86 | 0.17 |
| FAT BW (kg) | 27.1 ± 10.3 | 26.0 ± 10.0 | 0.41 |
| CIRCUMFERENCE (cm) | 105.4 ± 11.1 | 100.6 ± 9.00 | 0.01* |
| FIRST ECV (%) | 78.4 (120) | 75.0 (30) | 0.80 |
| STRUCT HEART DISEASE (%) | 90.2 (138) | 95.0 (38) | 0.53 |
| HEART FAILURE (%) | 35.3 (54) | 47.5 (19) | 0.09 |
| DIABETES (%) | 14.4 (22) | 10.0 (4) | 0.68 |
| THYROID NORMAL (%) | 37.9 (58) | 35.0 (14) | 0.66 |
| TSH | 1.79 ± 1.22 | 2.37 ± 0.99 | 0.06 |
| TSH NORMAL (%) | 41.8 (64) | 35.0 (14) | 0.79 |
| COPD (%) | 1.31 (2) | 2.50 (1) | 0.43 |
| RENAL FAILURE (%) | 24.2 (37) | 22.5 (9) | 0.53 |
| GFR (ml/min) | 217.5 ± 111.0 | 234.6 ± 123.6 | 0.43 |
| AF/AFL DURATION (days) | 120.6 ± 119.8 | 165.6 ± 277.0 | 0.99 |
| PREVIOUS HF (%) | 13.1 (20) | 20.0 (8) | 0.39 |
| NOW HF (%) | 3.27 (5) | 0.00 (0) | - |
| HB (G/L) | 141.9 ± 13.5 | 139.8 ± 15.1 | 0.31 |
| HT (%) | 42.1 ± 4.08 | 42.4 ± 4.80 | 0.64 |
| WBC (109/L) | 7.49 ± 1.86 | 7.17 ± 1.74 | 0.26 |
| GLU (mmol/L) | 6.23 ± 1.90 | 6.45± 2.90 | 0.61 |
| UREA (mmol/L) | 6.64 ± 2.24 | 6.65 ± 2.23 | 0.91 |
| CREAT (mmol/L) | 98.8 ± 18.4 | 92.0 ± 15.4 | 0.05 |
| K (MMOL/L) | 4.31 ± 0.41 | 4.31 ± 0.37 | 0.77 |
| NA (MMOL/L) | 139.0 ± 2.97 | 139.3 ± 2.56 | 0.93 |
| AST (U/L) | 26.9 ± 18.0 | 20.3 ± 4.24 | 0.22 |
| ALT (U/L) | 30.5 ± 20.9 | 23.1 ± 9.76 | 0.15 |
| CK (U/L) MB (U/L) | 123.3 ± 171.6 13.4 ± 7.99 | 90.6 ± 48.9 13.1 ± 6.66 | 0.08 0.74 |
| TN (U/L) | 0.03 ± 0.08 | 0.03 ± 0.02 | 0.95 |
| TEE (%) | 97.4 (149) | 100.0 (40) | 0.58 |
| ECHOCONTRAST (%) | 20.3 (31) | 25.0 (10) | 0.77 |
| LA (MM) | 50.8 ± 8.17 | 50.3 ± 6.95 | 0.90 |
| NORMAL LA <50MM (%) | 70 (45.8) | 17 (42.5) | 0.86 |
| LV TSD (mm) | 34.0 ± 7.14 | 32.6 ± 6.67 | 0.31 |
| NORMAL LV TSD <36mm (%) | 51.6 (79) | 57.5 (23) | 0.59 |
| LV TDD (MM) | 51.1 ± 6.32 | 48.6 ± 5.47 | 0.04* |
| NORMAL LV TDD <57mm (%) | 71.9 (110) | 85.0 (34) | 0.18 |
| LV TSV (ML) | 47.4 ± 22.6 | 44.5 ± 16.0 | 0.95 |
| NORMAL LV TSV <50ml (%) | 61.4 (94) | 57.5 (23) | 0.48 |
| LV TDV | 101.7 ± 33.1 | 102.1 ± 26.3 | 0.62 |
| NORMAL LV TDV <140ml (%) | 81.1 (124) | 82.5 (33) | 0.55 |
| EF (%) | 55.7 ± 8.55 | 56.4 ± 8.17 | 0.34 |
| NORMAL EF > 50% (%) | 69.9 (107) | 70.0 (28) | 1.00 |
| ASA CLASS | 0.02* | ||
| CLASS 1 | 1.96 (3) | 7.50 (3) | |
| CLASS 2 | 64.7 (99) | 35.0 (14) | |
| CLASS 3 | 30.7 (47) | 50.0 (20) | |
| CLASS 4 | 2.60 (4) | 7.50 (3) | |
| FIRST DIAGNOSIS | |||
| AH (%) | 55.6 (85) | 47.5 (19) | 0.46 |
| CAD (%) | 7.84 (12) | 2.50 (1) | 0.31 |
| CMP (%) | 6.54 (10) | 7.50 (3) | 0.73 |
| VALVE (%) | 18.3 (28) | 40.0 (16) | 0.01* |
| NONE (%) | 11.8 (18) | 2.50 (1) | 0.13 |
| ANESTHETIC | |||
| PROPOFOL DOSIS (mg) | 117.4 ± 32.0 | 122.5 ± 40.8 | 0.64 |
| ANTICOAGULATION | |||
| SINTROM (%) | 89.5 (137) | 90.0 (36) | 1.00 |
| HEPARIN (%) | 7.19 (11) | 10.0 (4) | 0.52 |
| NOAC (%) | 3.27 (5) | 0.00 (0) | 0.59 |
| ANTIARRHYTMIC DRUGS | |||
| AMIODARONE (%) | 69.9 (107) | 67.5 (27) | 0.92 |
| BETA BLOCKER (%) | 45.1 (69) | 45.0 (18) | 1.00 |
| CCB (%) | 6 (3.92) | 7 (17.5) | 0.01* |
| DIGITALIS (%) | 3.27 (5) | 5.00 (2) | 0.64 |
| PROPAFENONE (%) | 11.8 (18) | 2.50 (1) | 0.13 |
| NUMBER DRUGS | 1.34 ± 0.49 | 1.38 ± 0.54 | 0.85 |
| ACE INHIBITOR/ARB (%) | 64.7 (99) | 60.0 (24) | 0.74 |
| ATROPIN BEFORE (%) | 34.6 (53) | 37.5 (15) | 0.83 |
| HR BEFORE (bpm) | 93.6 ± 20.0 | 96.5 ± 19.7 | 0.32 |
| SYSTOLIC BP (mmHg) | 133.7 ± 16.5 | 132.4 ± 13.3 | 0.55 |
| DIASTOLIC BP (mmHg) | 85.1 ± 12.3 | 81.5 ± 11.1 | 0.04* |